Champions Oncology (CSBR) Q2 2026 earnings summary

Executive summary

• Year-to-date and quarterly results show strong revenue growth, improved margin performance, and positive adjusted EBITDA, with confidence in achieving full-year goals and no shareholder dilution.

• Oncology revenue increased 11.5% year-over-year for the quarter, reaching $15 million, driven by improved bookings-to-revenue conversion and fewer study cancellations.

• Net income for the quarter was $237,000, with adjusted EBITDA between $800,000 and $843,000; however, a net loss of $230,000 was recorded for the six months due to higher operating expenses.

• Ongoing investments in data licensing platforms and the Corelia/Corellia subsidiary focus on target discovery and technology-enabled research solutions.

• Management remains confident in ongoing growth, supported by operational efficiencies and strategic investments.

Financial highlights

• Quarterly revenue was $15 million, up 11–11.5% year-over-year from $13.5 million, with oncology services margin rising to 52% from 45%.

• Net income for the quarter was $237,000; adjusted EBITDA was approximately $800,000–$843,000.

• Cash and cash equivalents at period end were $8.5 million, with no debt.

• Operating expenses increased, mainly due to investments in the data platform and target discovery initiatives.

• Research and development expenses rose over 50% year-over-year, reflecting increased investment in data and discovery platforms.

Outlook and guidance

• On track to deliver year-over-year revenue growth and positive adjusted EBITDA for the full fiscal year.

• Management believes cash on hand and expected cash flows are adequate to fund operations through at least December 2026.

• Cautiously optimistic for booking momentum as pharma and biotech funding environments strengthen.

• Continued investment in data platform and core services expected to drive long-term growth, though may introduce short-term variability.